High blood pressure remains one of the most prevalent yet undertreated metabolic conditions worldwide. Traditional management often relies on medications that address symptoms without correcting underlying drivers such as insulin resistance, chronic inflammation, and mitochondrial dysfunction. Russell Clark’s clinical framework offers a comprehensive, hormone-centric protocol that targets these root causes, delivering sustainable blood pressure optimization alongside meaningful improvements in body composition and energy metabolism.
Clark’s methodology challenges the outdated CICO model, demonstrating that hypertension is rarely solved by salt restriction or calorie counting alone. Instead, it demands restoration of leptin sensitivity, enhancement of mitochondrial efficiency, and strategic modulation of incretin hormones including GLP-1 and GIP.
Understanding the Metabolic Roots of Hypertension
Hypertension frequently coexists with visceral adiposity, elevated HOMA-IR scores, and high-sensitivity C-Reactive Protein (hs-CRP). These markers reveal a state of chronic low-grade inflammation that stiffens arteries, promotes sodium retention, and impairs endothelial function. Clark’s initial assessment always includes advanced body composition analysis, fasting insulin, HOMA-IR, hs-CRP, and ketone production capacity to map each patient’s unique metabolic terrain.
When mitochondria become inefficient due to oxidative stress and intracellular debris, cells shift toward glucose dependency, driving hyperinsulinemia that directly elevates blood pressure. Restoring mitochondrial efficiency through targeted nutrition and lifestyle interventions becomes foundational to long-term blood pressure control.
The Anti-Inflammatory Protocol and Lectin Management
Central to Clark’s approach is a meticulously designed anti-inflammatory protocol that eliminates dietary triggers while maximizing nutrient density. High-lectin foods are minimized because they can increase intestinal permeability and elevate systemic inflammation, reflected in rising CRP levels. Patients transition to lectin-free, low-carbohydrate meals built around high-quality proteins, cruciferous vegetables such as bok choy, and low-glycemic berries.
This dietary shift rapidly lowers CRP, improves leptin sensitivity, and allows fat cells to release stored energy rather than hoard it. Patients report reduced hunger as the brain once again hears leptin’s “I am full” signal. The combination of nutrient-dense, anti-inflammatory eating and strategic timing creates a metabolic environment where blood pressure naturally trends downward.
Strategic Use of Incretin Therapies: GLP-1 and GIP
Clark integrates dual incretin pharmacology, particularly tirzepatide, which simultaneously targets GLP-1 and GIP receptors. GLP-1 slows gastric emptying, enhances satiety, and improves insulin sensitivity. GIP complements these effects by optimizing lipid metabolism and further refining appetite regulation within the central nervous system. Together they create powerful synergy that reduces visceral fat—the type most closely linked to resistant hypertension.
Rather than indefinite use, Clark employs a signature 30-Week Tirzepatide Reset. This protocol utilizes a single 60 mg box cycled thoughtfully across distinct phases to achieve metabolic transformation without creating lifelong dependency. Subcutaneous injections are administered with precise site rotation to maintain consistent absorption and minimize tissue irritation.
The 70-Day Metabolic Reset Cycle
The protocol unfolds in clearly defined stages. Phase 2, the 40-day Aggressive Loss window, combines low-dose tirzepatide with a strict lectin-free, low-carb framework to accelerate fat oxidation and ketone production. Patients shift into nutritional ketosis, using ketones as a clean energy source that also dampens inflammation and stabilizes blood pressure.
The subsequent Maintenance Phase spans 28 days and focuses on stabilizing the new body composition, reinforcing habits that protect mitochondrial efficiency, and gradually reintroducing carefully selected foods while monitoring HOMA-IR and CRP. This structured cycling retrains the metabolism to utilize stored fat for fuel, preventing the metabolic adaptation and BMR decline commonly seen in conventional weight loss.
Throughout the cycle, resistance training and red light therapy are prescribed to preserve lean muscle mass, sustain BMR, and enhance cellular energy production. Regular tracking of body composition ensures weight loss derives from fat, not muscle, preserving metabolic rate.
Clinical Outcomes and Long-Term Metabolic Resilience
Patients following Clark’s framework typically experience normalized blood pressure, reduced need for antihypertensive medications, significant drops in HOMA-IR, and normalized CRP. Many achieve sustained metabolic reset—restored leptin sensitivity, efficient fat burning, and stable energy levels without constant hunger.
The beauty of this approach lies in its departure from symptom management toward genuine physiological repair. By addressing inflammation, hormonal signaling, mitochondrial health, and nutrient density simultaneously, the protocol creates compounding benefits that extend far beyond blood pressure numbers.
Success ultimately depends on patient adherence to the full spectrum of interventions: precise nutrition, strategic medication cycling, movement protocols, and ongoing biomarker monitoring. Those who complete the 30-week reset and internalize the maintenance principles often maintain their improvements naturally, free from perpetual pharmacological dependence.
This comprehensive clinical model demonstrates that hypertension, when viewed through a metabolic lens, becomes a reversible condition rather than a lifelong sentence. With thoughtful integration of incretin science, anti-inflammatory nutrition, and mitochondrial support, lasting optimization is not only possible—it becomes the expected outcome.